Author: Megan Davis (Page 3)
Can Diabetes Monitors Help Dialysis Patients? A First Step Toward an Answer
New research attempts to help those with end-stage renal disease avoid extreme hypoglycemia.
The Results Are In: Focused Ultrasound’s Impact on Essential Tremor
A pivotal study shows the efficacy and safety of the treatment over time.
UVA Children’s Completes First Pediatric Stem Cell Transplant, Progressing Toward Filling a Key Gap in Care for Virginia Children
85% of Virginia children needing allogeneic transplants travel outside the state to receive them. UVA Children's completed an important milestone toward meeting this need.
The Brain & Immune System: Building on a Groundbreaking Discovery
Our discovery shocked the medical community. Now we're finding answers to the most devastating neurological disorders.
When a Children’s Hospital Advocates for Children With Spinal Muscular Atrophy
How one of only a few multidisciplinary treatment programs for SMA in Virginia cares for children throughout the region.
UVA Health Among Select Hospitals to Treat Fibromuscular Dysplasia
One of only 15 healthcare centers in the country with the expertise to treat FMD effectively, UVA Health Heart & Vascular is contributing to research efforts that could lead to new therapies for this complex and serious disease.
Ingredients for Success: Why This CTO Treatment Team Is Next Level
UVA Health is among the few high-volume cardiac care centers in the country with the requisite skills and dedicated expertise to tackle chronic total occlusion. Find out how we achieve high success rates and life-changing outcomes.
A 1-2 Punch: How a New Drug Combo Could Extend Lives
A UVA Health researcher and colleagues have found that a new drug combination may lengthen survival in patients with advanced non-squamous NSCLC.
UVA Health Turbocharges Focused Ultrasound Research
Discover the new worldwide leader in translational FUS immuno-oncology research.
The Molecular Landscape of LGL Leukemia: Defined & Refined
A team of UVA Health researchers has found evidence that screening for STAT3 mutations will help to better classify and diagnose patients with LGL leukemia.